BIRC5 and metastatic melanoma: Using the previously identified survivin peptide epitope Sur1M2 (LMLGEFLKL) [151, 152] and an indoleamine 2,3-dioxygenase (IDO) peptide (ALLEIASCL) as epitopes for vaccination in combination of the chemotherapy temozolomide, a Phase II study was conducted in metastatic melanoma patients [169].